Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Schey

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Leukemia|May 23, 2001
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemiaG Visani, D Milligan, F Leoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphomaS Rao, D Watkins, D Cunningham, et al.
British Journal of Haematology|February 13, 2001
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformationG Jackson, P Taylor, G M Smith, et al.
Cytotherapy|August 13, 2002
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
Blood|September 26, 2000
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Leukemia|May 23, 2001
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemiaG Visani, D Milligan, F Leoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphomaS Rao, D Watkins, D Cunningham, et al.
British Journal of Haematology|February 13, 2001
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformationG Jackson, P Taylor, G M Smith, et al.
Cytotherapy|August 13, 2002
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
Blood|September 26, 2000
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantationP D Kottaridis, D W Milligan, R Chopra, et al.
Pageof 4